

**899 NORTH CAPITOL ST. NE – 2<sup>ND</sup> FLR.  
WASHINGTON, DC 20002**

**August 4, 2022**

**9:30 am**

**OPEN SESSION AGENDA  
(VIA WEBEX MEETING DUE TO THE COVID-19 PUBLIC HEALTH EMERGENCY)**

**Board of Pharmacy Mission Statement:**

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

**CALL TO ORDER:**

**PRESIDING:**

**BOARD MEMBERSHIP/ATTENDANCE:**

BOARD MEMBERS:		
	DR. TAMARA McCANTS, PHARM.D. R.PH CHAIRPERSON	
	MR. ALAN FRIEDMAN, R.PH, VICE CHAIRPERSON	
	DR. BENJAMIN MILES, PHARM.D. R.PH	
	DR. ASHLEE BOW, PHARM.D. R.PH	
	DR. ALLISON HILL, PHARM.D. R.PH	
	MS. DONAE MAGETT, CONSUMER MEMBER	
STAFF:	DR. JUSTIN ORTIQUE, EXECUTIVE DIRECTOR	
	KARIN BARRON, HEALTH LICENSING SPECIALIST	
	LUANNE GREENAWAY, PROGRAM SPECIALIST	
	COUNTEE GILLIAM, BOARD INVESTIGATOR	
LEGAL STAFF:	CARLA WILLIAMS, SENIOR ASSISTANT GENERAL COUNSEL	
VISITORS:		

## Open Session Agenda

Quorum:

<b>Introduction:</b>		
<b>o804-O-01</b>	<b><u>Approval of the Open Session Meeting Minutes for:</u></b>  June 2, 2022 July 7, 2022	
<b><u>Consent Agenda</u></b>	<b>None</b>	
<b><u>Chairperson Report</u></b>	<b><u>Interprofessional Workgroup</u></b>	Dr. Tamara McCants
<b><u>Executive Director Report</u></b>	<ul style="list-style-type: none"> <li>▪ <b>Statistical Report on Pharmacy professionals in the District of Columbia</b></li> <li>▪ <b>Prescription Drug Monitoring Program Updates</b></li> <li>▪ <b>DCRx (DC Center for Rational Prescribing)</b></li> <li>▪ <b>District Addiction Consultation Service (DACs)</b></li> <li>▪ <b>District of Columbia Municipal Regulations For Pharmacies Chapter 19 Update</b></li> </ul>	Dr. Justin Ortique
<b><u>Senior Assistant General Counsel Report</u></b>		
<b>o804-O-02</b>	<b><u>Notice of Proposed Rulemaking</u></b>  (a) <b><u>Drafted 17 DCMR Chapter 65 Pharmacists Update</u></b>	Ms. Carla Williams
<b><u>Subcommittee Reports</u></b>		
<b>o804-O-03</b>	<b><u>Legislative and Regulatory Subcommittee Report</u></b>	Mr. Alan Friedman
<b>o804-O-04</b>	<b><u>Communications Subcommittee Report</u></b>	Dr. Ashlee Bow
<b><u>Matters for Consideration</u></b>	<b><u>FDA-Pharmacists prescribing Pfizer’s Paxlovid medication to treat COVID-19</u></b>  (a) FDA-U.S. Food & Drug Administration-Letter of Response to the Emergency Use Authorization (Eua) of Paxlovid for Coronavirus Disease 2019 (Covid-19) (b) Pfizer’s Paxlovid Fact Sheet for Patients, Parents, And Caregivers (c) Pfizer’s Paxlovid Fact Sheet For Healthcare Providers: Emergency Use Authorization For Paxlovid	

	(d) Maryland Department of Health-COVID-19 Therapeutics Team-FDA authorizes pharmacist to prescribe Paxlovid with certain limitations	
<b>NABP E-Newsletter</b>	<p><u>July 27, 2022</u></p> <p>Drug Overdose Deaths Rise, Health Disparities Worsen</p> <p>HHS Guidance Reminds Pharmacists to Follow Federal Civil Rights Laws When Filling Abortion and Birth Control Medications</p> <p>The Changing Role of Pharmacy Technicians Helps Pharmacists</p> <p>Q&amp;A with FDA” Podcast Series Conversation on Paxlovid and COVID-19</p> <p>DEA Seizes 100,000 Fake Oxycodone Pills Containing Fentanyl</p> <p>Most Older Adults Unaware of Medication Review Services, Interested to Learn More</p> <p>PTCB Launches Supply Chain and Inventory Management Certificate</p> <p><u>July 20, 2022</u></p> <p>Older Patients More Likely to Have Drug Interactions With Paxlovid</p> <p>Pfizer-BioNTech COVID-19 Vaccine Approved for Children Aged 12-15</p> <p>Central Sensitization: The Link Between Opioid Misuse and Chronic Pain?</p> <p>Recognize National Immunization Awareness Month in August</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link:  <a href="https://nabp.pharmacy/newsroom/news/">https://nabp.pharmacy/newsroom/news/</a>.</p>	Dr. Tamara McCants
<b><u>Comments from the Public</u></b>		
<b><u>Motion to Adjourn the Open Session</u></b>	<p>“Madam Board Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14).” ROLL CALL VOTE</p>	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

**Open Session Meeting Adjourned at \_:\_ AM.**

**This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at [opengovoffice@dc.gov](mailto:opengovoffice@dc.gov).**